Zak's view27 Mar 2021 12:29
Taken from the Sharetalk website:
The other big play of last year, still very much in focus this year, has been Eurasia Mining (EUA). The latest news from the palladium focused group, still in sale talks, is that it has signed a legally binding agreement to create a new joint venture with Russian state-owned company, expanding Eurasia’s world-class portfolio of mining assets on the Kola Peninsula. The Rosgeo Agreement allows Eurasia to gain a 75% equity stake in each of the nine new mining assets for just $0.5m. The remaining 25% equity stakes will continue to be held by Rosgeo. On the face of it this seemed to be something of a steal for Eurasia, instantly growing the already near £1bn valuation company to a new higher net asset value. Interestingly enough, if any sale price / deal had been in the mix before the latest announcement, it would either be much more easily justified, or may have to be revised upwards. As is EUA’s wont, the news came after the stock market close, ahead of which the shares were up 5%.
Multidivisional new media and technology business Iconic Labs (ICON) announced that it has signed a settlement agreement with EHGOF with respect to claims made by EHGOF in connection with alleged breaches of various finance agreements. New CEO Brad Taylor said that settling these claims with EHGOF was an immediate priority, with the goal now being to continue to work productively with EHGOF. The result of peace breaking out between the two parties was a 33% share price rise for Iconic.
While almost all the testing stocks have seen an element of disappointment/cooling off of their share prices in the recent past, Braveheart International (BRH) has been able to celebrate with a 48% share price rise. This came in the wake of the company’s revelation that the Paraytec team has used isolated lab-grown COVID-19 virus to optimise the operational sensitivity of its instrument for the detection of pre-symptomatic and early-stage symptomatic virus levels. Using this approach, the team has established a lower limit of detection of 1,000 virions per millilitre of sample fluid analysed. This would represent a significantly better performance than the lateral flow tests that are currently authorised for emergency use to detect infectivity and which typically have a lower limit of detection of 10,000-100,000 virions per sample.